Compare BGSF & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGSF | IFRX |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.4M | 60.6M |
| IPO Year | 2013 | 2017 |
| Metric | BGSF | IFRX |
|---|---|---|
| Price | $6.00 | $0.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $9.00 | $8.50 |
| AVG Volume (30 Days) | 21.5K | ★ 302.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 33.33% | N/A |
| EPS Growth | ★ 67.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $272,499,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.14 | $1,054.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.91 | $0.71 |
| 52 Week High | $8.20 | $1.94 |
| Indicator | BGSF | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.90 | 50.34 |
| Support Level | $6.01 | $0.73 |
| Resistance Level | $6.38 | $1.16 |
| Average True Range (ATR) | 0.25 | 0.05 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 59.35 | 75.05 |
BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.